



AveXis Statement on Changes to Senior Leadership Team

August 14, 2019

AveXis announces Page Bouchard, DVM has been appointed Senior Vice President of Research and Chief Scientific Officer, effective August 5, 2019. Dr. Bouchard is a 27-year industry veteran with experience in well over 100 Investigational New Drug programs and dozens of New Drug Application/Biologics License Application filings. He has been with Novartis for 10 years and most recently was the Global Head of Preclinical Safety for Novartis Institutes for BioMedical Research (NIBR).

The roles of Head of Research and Development and Chief Scientific Officer, previously held by Brian Kaspar, PhD, Chief Scientific Officer and Allan Kaspar, PhD, Senior Vice President Research and Development, will be combined in Dr. Bouchard's new role. Brian Kaspar and Allan Kaspar have not been involved in any operations at AveXis since early May 2019 and are no longer with the company.